BIO — Bio-Rad Laboratories Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $366.36
- YTD price return
- +20.91%
- YTD total return
- +20.91%
- Market cap
- 9.9B
- Enterprise value
- 9.6B
- Shares outstanding
- 26.9M
- 52W low
- $236.73
- 52W high
- $396.23
- From 52W high
- -7.54%
- From 52W low
- +54.76%
- 52W range
- 81%$237–$396
Volume
- Rel volume
- 1.04×
- 30D volume
- 244.6K
- 30D $ vol
- 90.8M
Insider trading
- Insider net 1W
- −$1.2M
- Insider net 1M
- −$1.2M
- Insider net 3M
- −$1.2M
- Insider net 1Y
- −$1.4M
Form 4 transactions by trade date, as filed; latest on file 2026-11-10.
Fundamentals
- Sales (ttm)
- 2.6B
- Sales/share
- $96.41
- EPS (ttm)
- $37.98
- FCF (ttm)
- 329.1M
- FCF/share
- $12.24
- Book value/share
- $282.71
- Net margin
- 39.45%
- ROE
- 13.45%
- ROA
- 9.49%
- Debt / equity
- 0.11×
- Current ratio
- 3.18
Growth (CAGR, ttm) · 10Y
- Sales
- +1.38%-1.59%-2.74%+2.29%
- Net income
- n/an/a-31.27%+45.76%
- FCF
- -2.29%+13.64%-13.17%+25.88%
- Shares
- -0.30%-2.64%-2.11%-0.98%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- n/an/a-29.66%+28.13%
- Sales/share
- +1.69%+1.09%-0.65%+3.30%
- FCF/share
- -1.99%+16.72%-11.29%+27.12%
- Book value/share
- +13.21%-0.70%-11.22%+11.99%
- Price
- +15.62%+6.44%-13.49%+8.19%
- Total return
- +15.62%+6.44%-13.49%+8.19%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 9.6×
- P/OI (ttm)
- 191.1×
- Fwd P/E
- 37.2×
- P/S (ttm)
- 3.8×
- P/B (mrq)
- 1.3×
- P/FCF (ttm)
- 29.9×
- EV/Sales (ttm)
- 3.7×
- FCF yield (ttm)
- 3.34%
- Buyback yield (realized, 1y)
- 0.30%
- Shareholder yield (realized, 1y)
- 0.30%
- Buyback yield (cash, ttm)
- 0.80%
- Shareholder yield (cash, ttm)
- 0.80%
Vs own 10Y history
- P/E
- 45th
- P/OI
- 98th
- P/S
- 47th
- P/B
- 29th
- P/FCF
- 19th
Bar = where today’s multiple sits in BIO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR −35.5%10Y CAGR −11.9%YoY n/mEPS (diluted)
5Y CAGR −26.1%10Y CAGR +22.3%YoY n/mFree cash flow
5Y CAGR −4.7%10Y CAGR +17.6%YoY −26.9%TTM: operating cash flow $468.1M, capex −$139M
Q3 2026: operating cash flow $96.4M, capex −$31.2M
Shares (diluted)
5Y −9.5%10Y −7.2%YoY +0.1%Net income
5Y CAGR −27.6%10Y CAGR +21.4%YoY n/mAbout Bio-Rad Laboratories#
Data provided bySource: Twelve DataBio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.
Hercules, CA·7,450 employees·Medical Devices·bio-rad.com·As of Oct 30, 2026
Recent filings#
- Nov 10Insider sale · ENLOE COURTNEY C (EVP, General Counsel & Sec) sold 902 shares for $348K at $386.17
- Nov 9Insider sale · BARRY JAMES (EVP, President, LSG) sold 1,400 shares for $540K at $385.63
- Nov 9Insider sale · DiVincenzo Jonathan P. (President & COO) sold 919 shares for $359K at $390.47
- Nov 4Earnings · Earnings release — EPS $2.65 vs $2.61 est. (+1.5%); revenue $656.4M (+1% y/y) 2.9%
- Aug 4Earnings · Earnings release — EPS $2.62 vs $2.34 est. (+12.0%); revenue $651.0M (−0% y/y) 4.5%
ETFs holding BIO#
19 of the 193 ETFs ChartRow carries live hold BIO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IJH | iShares Core S&P Mid-Cap ETF | 0.1% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.1% |
| VBR | Vanguard Small-Cap Value ETF | 0.1% |
| VHT | Vanguard Health Care ETF | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
